IBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

- ShieldTx potentially increases safety and developability of therapeutic antibodies for difficult targets and modes of action - BRYAN, Texas and SAN DIEGO, Nov. 01, 2023 -- iBio, Inc. today...

Related Keywords

United States ,Texas ,American ,Matt Greving ,Susan Thomas ,Stephen Kilmer ,Martin Brenner ,Globenewswire Inc ,Bio Inc ,Company Annual Report On Form ,While The Company ,Drug Discovery Platform ,Epitope Steering ,Machine Learning ,Platform Technologies ,Chief Executive Officer ,Chief Scientific Officer ,Biological Therapy ,Annual Report ,Markets ,